AMAG Pharma’s licensing deal with Palatin Technologies for North American rights to Rekynda
Posted on07 Feb 2017
Comments0
AMAG Pharmaceuticals has announced licensing agreement with Palatin Technologies, for exclusive North American commercial rights to Rekynda (bremelanotide), an investigational product developed... Read More